Use of the approved therapy Imaavy (nipocalimab-aahu) leads to a lasting drop in symptoms and related gains in quality…
Patricia Inacio, PhD
Science Writer
Patrícia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. Her expertise started in cell biology, later extending to stem cells and patient-derived cancer organoids at the University of Cambridge, UK. She was selected to an international PhD program, was the recipient of several fellowships to conduct her PhD studies in Portugal and the U.S., and has been an invited speaker across international conferences.
Education
- PhD in Cell Biology, University Nova de Lisboa, Portugal, 2013
- MSc in Biology, 2007
Published Works
- van Tienderen GS, (…), Inacio, P. et al, Cancer Cell. 2022 Mar 14;40(3):226-230.
- Inacio, P. et al, Gut. 2019 Dec;68(12):2228-2237.
- Inacio, P. et al, EMBO Rep. 2015 Aug;16(8):955-64.
- Pinheiro, H (…), Inacio, P. et al, Hum Mol Genet. 2010 Mar 1;19(5):943-52.
Professional Accomplishments
- 2012, Scholarship from Luso-American Development Foundation (Portugal/USA) to perform research at Columbia University, New York
- 2007, Winner of the 1st prize of “Grant Proposal” Final Exercise of Gulbenkian PhD Program
- 2007, PhD Scholarship from Fundação para a Ciência e Tecnologia (Portugal)
- 2007, Selected for the International Gulbenkian PhD Program, at Instituto Gulbenkian de Ciência (IGC), Lisbon, Portugal
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Patricia Inacio, PhD
For most people with mild, stable myasthenia gravis (MG), taking a low dose of trazodone hydrochloride, an oral…
People with myasthenia gravis (MG) who lack detectable MG-related antibodies, known as seronegative MG, may be rarer than previously…
Treatment with Vyvgart (efgartigimod) was associated with rapid and sustained symptom easing, lower corticosteroid use, and no unexpected safety…
A new U.S.-based patient registry is enrolling people with myasthenia gravis (MG) to help researchers better understand how the disease…
Ocular myasthenia gravis (OMG) patients with abnormalities in the thymus gland, antibodies against the AChR protein, or a history…
An elevated triglyceride-glucose (TyG) index, a blood marker of insulin resistance, may be a useful biomarker to identify people at…
Some people with well-controlled myasthenia gravis (MG) may be able to stop azathioprine or mycophenolate mofetil after a…
Measuring changes in blood levels of two proteins — neurofilament light chain (NfL) and calprotectin (CLP) — may show how…
Black patients with generalized myasthenia gravis (gMG) face significantly higher risks of exacerbations compared with their white counterparts, according…